Company No:
Contents
| Note | 2025 | 2024 | ||
| £ | £ | |||
| Fixed assets | ||||
| Tangible assets | 5 |
|
|
|
| Investments | 6 |
|
|
|
| 1,448,218 | 1,278,909 | |||
| Current assets | ||||
| Stocks |
|
|
||
| Debtors | 7 |
|
|
|
| Cash at bank and in hand |
|
|
||
| 845,428 | 1,063,088 | |||
| Creditors: amounts falling due within one year | 8 | (
|
(
|
|
| Net current assets | 197,272 | 424,025 | ||
| Total assets less current liabilities | 1,645,490 | 1,702,934 | ||
| Provision for liabilities | (
|
(
|
||
| Net assets |
|
|
||
| Capital and reserves | ||||
| Called-up share capital |
|
|
||
| Profit and loss account |
|
|
||
| Total shareholders' funds |
|
|
Directors' responsibilities:
The financial statements of Devkipharm Limited (registered number:
|
R Patel
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.
Devkipharm Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 2 Hales Drive, Canterbury, Kent, CT2 7AB, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
Group accounts exemption s399
The Company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the Company as an individual entity and not about its group.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
| Goodwill |
|
| Land and buildings |
|
| Fixtures and fittings |
|
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.
| 2025 | 2024 | ||
| Number | Number | ||
| Monthly average number of persons employed by the Company during the year, including directors: |
|
|
| Goodwill | Total | ||
| £ | £ | ||
| Cost | |||
| At 01 August 2024 |
|
|
|
| At 31 July 2025 |
|
|
|
| Accumulated amortisation | |||
| At 01 August 2024 |
|
|
|
| At 31 July 2025 |
|
|
|
| Net book value | |||
| At 31 July 2025 |
|
|
|
| At 31 July 2024 |
|
|
| Land and buildings | Fixtures and fittings | Total | |||
| £ | £ | £ | |||
| Cost | |||||
| At 01 August 2024 |
|
|
|
||
| Additions |
|
|
|
||
| At 31 July 2025 |
|
|
|
||
| Accumulated depreciation | |||||
| At 01 August 2024 |
|
|
|
||
| Charge for the financial year |
|
|
|
||
| At 31 July 2025 |
|
|
|
||
| Net book value | |||||
| At 31 July 2025 | 1,233,260 | 213,691 | 1,446,951 | ||
| At 31 July 2024 | 1,059,115 | 218,527 | 1,277,642 |
Investments in subsidiaries
| 2025 | |
| £ | |
| Cost | |
| At 01 August 2024 |
|
| At 31 July 2025 |
|
| Carrying value at 31 July 2025 |
|
| Carrying value at 31 July 2024 |
|
| Other investments | Total | ||
| £ | £ | ||
| Cost or valuation before impairment | |||
| At 01 August 2024 |
|
|
|
| At 31 July 2025 |
|
|
|
| Carrying value at 31 July 2025 |
|
|
|
| Carrying value at 31 July 2024 |
|
|
| 2025 | 2024 | ||
| £ | £ | ||
| Trade debtors |
|
|
|
| Amounts owed by connected persons |
|
|
|
| Other debtors |
|
|
|
|
|
|
| 2025 | 2024 | ||
| £ | £ | ||
| Trade creditors |
|
|
|
| Amounts owed to Group undertakings |
|
|
|
| Amounts owed to connected companies |
|
|
|
| Taxation and social security |
|
|
|
| Other creditors |
|
|
|
|
|
|
Transactions with owners holding a participating interest in the entity
| 2025 | 2024 | ||
| £ | £ | ||
| Amounts owed to a group company: | 225,389 | 225,389 | |
| Amounts owed to a group company: | 19,683 | 4,798 | |
| Amounts owed to a company related by common control: | 236,968 | 236,968 | |
| Amounts owed to a group company: | 8 | 8 |
Transactions with the entity's directors
| 2025 | 2024 | ||
| £ | £ | ||
| Amounts owed to a director: | 8,736 | 7,783 |